{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:45:15Z","timestamp":1785764715584,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MedScience"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Infliximab (IFX) for inflammatory bowel disease (IBD) treatment may increase the risk of hepatitis B virus (HBV) reactivation, particularly in areas with high HBV prevalence such as China. This study aimed to evaluate HBV reactivation\/infection, liver dysfunction, vaccination efficacy and strategies in IBD patients undergoing IFX therapy. This retrospective, multicenter study included 4183 IBD patients from 15 hospitals across China, who were divided into six groups according to the HBV status. Demographic features, HBV vaccination status, reactivation\/infection rates, and liver dysfunction outcomes were collected, with data collection performed from 2009 to 2022. We found that HBV reactivation rate was notably higher in HBsAg positive group than other groups (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.05) despite antiviral treatment. Although only 29% of patients were immunized at IFX initiation and almost no patients got vaccinated against HBV during IFX treatment, no patients experienced HBV infection in the susceptible population group. The study underscores a critical need for rigorous HBV screening before IFX initiation. Despite antiviral prophylaxis, the importance of continuous monitoring of HBV DNA is necessary for HBsAg positive patients. HBsAg negative patients, including the susceptible population, had a very low risk of new HBV infection, thus reassuring patients and physicians of the safety of IFX in this cohort.\n                  <\/jats:p>","DOI":"10.1007\/s11684-026-1208-0","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:36:09Z","timestamp":1778034969000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis B virus infection or reactivation and HBV-related liver dysfunction in patients with inflammatory bowel disease receiving infliximab: a nationwide real-world study"],"prefix":"10.1007","volume":"20","author":[{"given":"Rongbei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"7","key":"1208_CR1","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","volume":"70","author":"GR D\u2019Haens","year":"2021","unstructured":"D\u2019Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021; 70(7): 1396\u20131405","journal-title":"Gut"},{"key":"1208_CR2","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(5 Suppl): S156\u2013S165","journal-title":"Hepatology"},{"issue":"6","key":"1208_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","volume":"90","author":"R P\u00e9rez-Alvarez","year":"2011","unstructured":"P\u00e9rez-Alvarez R, D\u00edaz-Lagares C, Garc\u00eda-Hern\u00e1ndez F, Lopez-Roses L, Brito-Zer\u00f3n P, P\u00e9rez-de-Lis M, Retamozo S, Bov\u00e9 A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M; BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90(6): 359\u2013371","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"1208_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem D, Prince AM. Hepatitis B virus infection\u2014natural history and clinical consequences. N Engl J Med 2004; 350(11): 1118\u20131129","journal-title":"N Engl J Med"},{"issue":"12","key":"1208_CR5","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","volume":"16","author":"MP Pauly","year":"2018","unstructured":"Pauly MP, Tucker LY, Szpakowski JL, Ready JB, Baer D, Hwang J, Lok AS. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2018; 16(12): 1964\u20131973.e1","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1208_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.gtc.2020.01.001","volume":"49","author":"H Razavi","year":"2020","unstructured":"Razavi H. Global epidemiology of viral hepatitis. Gastroenterol Clin North Am 2020; 49(2): 179\u2013189","journal-title":"Gastroenterol Clin North Am"},{"issue":"6","key":"1208_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","unstructured":"Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3(6): 383\u2013403","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1208_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/hbsn-2024-754","volume":"14","author":"R Yan","year":"2025","unstructured":"Yan R, Sun M, Yang H, Du S, Sun L, Mao Y. 2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges. Hepatobiliary Surg Nutr 2025; 14(1): 66\u201377","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1208_CR9","first-page":"101193","volume":"51","author":"Z Hui","year":"2024","unstructured":"Hui Z, Yu W, Fuzhen W, Liping S, Guomin Z, Jianhua L, Feng W, Ning M, Jian L, Guowei D, Tongtong M, Lin T, Shuang Z, Mingshuang L, Yuan L, Xiaoqi W, Qianqian L, Qian Z, Dan W, Tingting Y, Qiudong S, Miao W, Li L, Qian H, Yixing L, Yi L, Shaodong Y, Zhijie A, Rodewald LE, Jidong J, Huaqing W, Wenzhou Y, Zhongfu L, Qun L, Zijian F, Zundong Y, Yu W. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health West Pac 2024; 51: 101193","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"1208_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021; 15(5): 1031\u20131048","journal-title":"Hepatol Int"},{"issue":"2","key":"1208_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.vaccine.2017.07.046","volume":"37","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017\u2014Recommendations. Vaccine 2019; 37(2): 223\u2013225","journal-title":"Vaccine"},{"issue":"9959","key":"1208_CR12","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","volume":"384","author":"C Tr\u00e9po","year":"2014","unstructured":"Tr\u00e9po C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384(9959): 2053\u20132063","journal-title":"Lancet"},{"issue":"2","key":"1208_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1053\/j.gastro.2021.04.034","volume":"161","author":"JL Jones","year":"2021","unstructured":"Jones JL, Tse F, Carroll MW, deBruyn JC, McNeil SA, Pham-Huy A, Seow CH, Barrett LL, Bessissow T, Carman N, Melmed GY, Vanderkooi OG, Marshall JK, Benchimol EI. Canadian Association of Gastroenterology Clinical Practice Guideline for immunizations in patients with inflammatory bowel disease (IBD)\u2014Part 2: inactivated vaccines. Gastroenterology 2021; 161(2): 681\u2013700","journal-title":"Gastroenterology"},{"issue":"6","key":"1208_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF; European Crohn\u2019s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8(6): 443\u2013468","journal-title":"J Crohns Colitis"},{"issue":"5","key":"1208_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrgastro.2013.28","volume":"10","author":"JP Gisbert","year":"2013","unstructured":"Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013; 10(5): 277\u2013285","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1208_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.crohns.2012.03.001","volume":"7","author":"A Papa","year":"2013","unstructured":"Papa A, Felice C, Marzo M, Andrisani G, Armuzzi A, Covino M, Mocci G, Pugliese D, De Vitis I, Gasbarrini A, Rapaccini GL, Guidi L. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-\u03b1 agents. J Crohns Colitis 2013; 7(2): 113\u2013119","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1208_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10620-017-4716-6","volume":"63","author":"HV Pham","year":"2018","unstructured":"Pham HV, Hasan I, Udaltsova N, Pham K, Abramson O, Armstrong MA, Postlethwaite D, Li D. Rates and predictors of vaccinations among inflammatory bowel disease patients receiving anti-tumor necrosis factor agents. Dig Dis Sci 2018; 63(1): 209\u2013217","journal-title":"Dig Dis Sci"},{"issue":"6","key":"1208_CR18","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/vaccines10060900","volume":"10","author":"X Bai","year":"2022","unstructured":"Bai X, Chen L, Liu X, Tong Y, Wang L, Zhou M, Li Y, Hu G. Adult hepatitis B virus vaccination coverage in China from 2011 to 2021: a systematic review. Vaccines (Basel) 2022; 10(6): 900","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1208_CR19","doi-asserted-by":"publisher","first-page":"10845","DOI":"10.1038\/s41598-024-61583-5","volume":"14","author":"H Guan","year":"2024","unstructured":"Guan H, Zhang L, Chen X, Zhang Y, Ding Y, Liu W. Enhancing vaccination uptake through community engagement: evidence from China. Sci Rep 2024; 14(1): 10845","journal-title":"Sci Rep"},{"issue":"10","key":"1208_CR20","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/ajg.2012.79","volume":"107","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Villagrasa JR, Rodr\u00edguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107(10): 1460\u20131466","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1208_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/MIB.0b013e31827febe9","volume":"19","author":"JP Gisbert","year":"2013","unstructured":"Gisbert JP, Villagrasa JR, Rodr\u00edguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(3): 554\u2013558","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1208_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s10620-011-1980-8","volume":"57","author":"ME Altun\u00f6z","year":"2012","unstructured":"Altun\u00f6z ME, Senate\u015f E, Ye\u015fil A, Calhan T, Ov\u00fcn\u00e7 AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012; 57(4): 1039\u20131044","journal-title":"Dig Dis Sci"},{"issue":"11","key":"1208_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.crohns.2014.06.009","volume":"8","author":"C Loras","year":"2014","unstructured":"Loras C, Gisbert JP, Saro MC, Piqueras M, S\u00e1nchez-Montes C, Barrio J, Ord\u00e1s I, Montserrat A, Ferreiro R, Zabana Y, Chaparro M, Fern\u00e1ndez-Ba\u00f1ares F, Esteve M; REPENTINA study, GETECCU group (Grupo Espa\u00f1ol de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J Crohns Colitis 2014; 8(11): 1529\u20131538","journal-title":"J Crohns Colitis"},{"issue":"8","key":"1208_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/apt.16880","volume":"55","author":"AK Singh","year":"2022","unstructured":"Singh AK, Jena A, Mahajan G, Mohindra R, Suri V, Sharma V. Meta-analysis: hepatitis B vaccination in inflammatory bowel disease. Aliment Pharmacol Ther 2022; 55(8): 908\u2013920","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"1208_CR25","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s10620-019-05595-6","volume":"64","author":"PK Pratt Jr","year":"2019","unstructured":"Pratt PKJr, Nunes D, Long MT, Farraye FA. Improved antibody response to three additional hepatitis B vaccine doses following primary vaccination failure in patients with inflammatory bowel disease. Dig Dis Sci 2019; 64(7): 2031\u20132038","journal-title":"Dig Dis Sci"},{"issue":"3","key":"1208_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MAJ.0b013e31821ff728","volume":"343","author":"T Ali","year":"2012","unstructured":"Ali T, Yun L, Shapiro D, Madhoun MF, Bronze M. Viral infections in patients with inflammatory bowel disease on immunosuppressants. Am J Med Sci 2012; 343(3): 227\u2013232","journal-title":"Am J Med Sci"},{"issue":"6","key":"1208_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/1751-2980.12994","volume":"22","author":"Inflammatory Bowel Disease Group","year":"2021","unstructured":"Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021; 22(6): 298\u2013317","journal-title":"J Dig Dis"},{"issue":"6","key":"1208_CR28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","volume":"15","author":"T Kucharzik","year":"2021","unstructured":"Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis 2021; 15(6): 879\u2013913","journal-title":"J Crohns Colitis"},{"issue":"23","key":"1208_CR29","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462\u20132476","journal-title":"N Engl J Med"},{"issue":"6","key":"1208_CR30","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1080\/21645515.2020.1847951","volume":"17","author":"X Zhao","year":"2021","unstructured":"Zhao X, Shi X, Lv M, Yuan B, Wu J. Prevalence and factors associated with hepatitis B virus infection among household members: a cross-sectional study in Beijing. Hum Vaccin Immunother 2021; 17(6): 1818\u20131824","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1208_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.7150\/ijms.8.321","volume":"8","author":"H Zhang","year":"2011","unstructured":"Zhang H, Li Q, Sun J, Wang C, Gu Q, Feng X, Du B, Wang W, Shi X, Zhang S, Li W, Jiang Y, Feng J, He S, Niu J. Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. Int J Med Sci 2011; 8(4): 321\u2013331","journal-title":"Int J Med Sci"},{"issue":"3","key":"1208_CR32","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3899\/jrheum.140853","volume":"42","author":"KJ Aaltonen","year":"2015","unstructured":"Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Piril\u00e4 L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordstr\u00f6m D. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 2015; 42(3): 372\u2013378","journal-title":"J Rheumatol"},{"issue":"12","key":"1208_CR33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1111\/jdv.18407","volume":"36","author":"YC Wang","year":"2022","unstructured":"Wang YC, Lin YH, Ma SH, Chang YT, Chen CC. Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2022; 36(12): 2301\u20132315","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1208_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/1756-185X.14034","volume":"24","author":"S Fidan","year":"2021","unstructured":"Fidan S, Capk\u0131n E, Ar\u0131ca DA, Durak S, Okatan IE. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-\u03b1 therapy. Int J Rheum Dis 2021; 24(2): 254\u2013259","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"1208_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.55563\/clinexprheumatol\/c25fja","volume":"39","author":"MC Ditto","year":"2021","unstructured":"Ditto MC, Parisi S, Varisco V, Talotta R, Batticciotto A, Antivalle M, Gerardi MC, Agosti M, Borrelli R, Fusaro E, Sarzi-Puttini P. Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy. Clin Exp Rheumatol 2021; 39(3): 546\u2013554","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"1208_CR36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/apt.17155","volume":"56","author":"H El Jamaly","year":"2022","unstructured":"El Jamaly H, Eslick GD, Weltman M. Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. Aliment Pharmacol Ther 2022; 56(7): 1104\u20131118","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1208_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.5217\/ir.2021.00106","volume":"20","author":"A Mishra","year":"2022","unstructured":"Mishra A, Puri AS, Sachdeva S, Dalal A. Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study. Intest Res 2022; 20(4): 445\u2013451","journal-title":"Intest Res"},{"key":"1208_CR38","doi-asserted-by":"publisher","first-page":"1327492","DOI":"10.1155\/2017\/1327492","volume":"2017","author":"HV Sahana","year":"2017","unstructured":"Sahana HV, Sarala N, Prasad SR. Decrease in anti-HBs antibodies over time in medical students and healthcare workers after hepatitis B vaccination. BioMed Res Int 2017; 2017: 1327492","journal-title":"BioMed Res Int"}],"container-title":["MedScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1208-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-026-1208-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1208-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:49:40Z","timestamp":1785761380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-026-1208-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1208"],"URL":"https:\/\/doi.org\/10.1007\/s11684-026-1208-0","relation":{},"ISSN":["3091-4973","3091-4981"],"issn-type":[{"value":"3091-4973","type":"print"},{"value":"3091-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Rongbei Liu, Tingting Wu, Jian Tang, Hongjie Zhang, Yanyun Fan, Haibo Sun, Chen Xie, Qunyan Zhou, Hongzhen Xu, Yabi Zhu, Mei Ye, Xiaomin Shi, Feng Tian, Haiyan Shen, Dan Xu, Ying Zhou, and Qian Cao declare that there is no conflict of interests in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This study was approved by the Ethics Committee of Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine (approval number 2022Y0356), and the study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Due to the retrospective nature of this study and the anonymity of its participants, the ethics committee waived the requirement for written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}